Additionally, we found that DAXX deficiency rendered GEP-NET cells sensitive to ATR inhibitors, while ARID1A mutation in GEP-NEC cells promoted synthetic lethality upon Aurora kinase A inhibition. This evidence concerns the gene ARID1A and neuroendocrine carcinoma.